Celltrion Pharm

At a glance

Celltrion Pharm filed 43 disclosures in the last 12 months, including 10 insider, 3 earnings, 1 5% holder and 1 buyback. The most recent key filing was on Aug 4.

Revenue for 2025 was ₩536B, up 12.3% on 2024. Operating margin was 10.5% against 7.8% a year earlier. Debt was 74% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩285B and operating profit of ₩32.2B.

The 2025 annual report lists 1,006 employees with an average tenure of 6.3 years and average pay of ₩77.2M, #436 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩178M each on average. It paid ₩200 per common share in cash dividends. (주)셀트리온 and related parties held 54.95% at year end.

From the 2025 annual report

Staff: 1,006 (711 men, 295 women), of whom 94 on fixed-term contracts. Total pay for the year: ₩77.9B. Directors and auditors: 9, paid ₩1.6B in total.

Dividends (common shares)

Largest shareholder

(주)셀트리온 holds 54.80%; with 12 related parties the group holds 54.95% of common shares at year end (from 54.94% at the start of the year).

Individuals paid ₩500M or more

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary